VKTX
Income statement / Annual
Last year (2025), Viking Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Viking Therapeutics Inc's net income was -$359.64 M.
See Viking Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$431.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$260.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$431.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$260.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$344.96 M
|
$101.64 M
|
$63.81 M
|
$54.23 M
|
$44.98 M
|
$31.93 M
|
$23.56 M
|
$19.04 M
|
$13.74 M
|
$9.00 M
|
| General & Administrative Expenses |
$48.39 M
|
$49.28 M
|
$37.02 M
|
$16.12 M
|
$10.70 M
|
$10.73 M
|
$0.00
|
$7.12 M
|
$5.33 M
|
$4.85 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$48.39 M
|
$49.28 M
|
$37.02 M
|
$16.12 M
|
$10.70 M
|
$10.73 M
|
$8.87 M
|
$7.12 M
|
$5.33 M
|
$4.85 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$393.34 M
|
$150.92 M
|
$100.83 M
|
$70.36 M
|
$55.68 M
|
$42.66 M
|
$32.43 M
|
$26.16 M
|
$19.07 M
|
$13.85 M
|
| Cost And Expenses |
$393.34 M
|
$150.92 M
|
$100.83 M
|
$70.36 M
|
$55.68 M
|
$42.66 M
|
$32.69 M
|
$26.16 M
|
$19.07 M
|
$13.85 M
|
| Interest Income |
$33.70 M
|
$40.94 M
|
$15.02 M
|
$1.59 M
|
$703.00 K
|
$3.23 M
|
$7.05 M
|
$3.27 M
|
$98.14 K
|
$83.62 K
|
| Interest Expense |
$56.00 K
|
$94.00 K
|
$88.00 K
|
$59.00 K
|
$18.00 K
|
$106.00 K
|
$146.00 K
|
$562.00 K
|
$1.95 M
|
$2.03 M
|
| Depreciation & Amortization |
$431.00 K
|
$346.00 K
|
$292.00 K
|
$291.00 K
|
$296.00 K
|
$277.00 K
|
$260.00 K
|
$26.16 M
|
$19.07 M
|
$13.85 M
|
| EBITDA |
-$393.34 M |
-$150.58 M |
-$100.54 M |
-$70.06 M |
-$55.39 M |
-$39.11 M |
-$25.37 M |
$4.66 M |
$442.88 K |
$1.15 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$33.70 M
|
$40.96 M
|
$14.93 M
|
$1.49 M
|
$692.00 K
|
$3.17 M
|
$6.91 M
|
$4.10 M
|
-$1.51 M
|
-$884.55 K
|
| Income Before Tax |
-$359.64 M
|
-$109.96 M
|
-$85.90 M
|
-$68.87 M
|
-$54.99 M
|
-$39.50 M
|
-$25.78 M
|
-$22.06 M
|
-$20.58 M
|
-$14.73 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$359.64 M
|
-$109.96 M
|
-$85.90 M
|
-$68.87 M
|
-$54.99 M
|
-$39.50 M
|
-$25.78 M
|
-$22.06 M
|
-$20.58 M
|
-$14.73 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.19 |
-1.01 |
-0.91 |
-0.88 |
-0.7 |
-0.5 |
-0.36 |
-0.38 |
-0.79 |
-0.9 |
| EPS Diluted |
-3.19 |
-1.01 |
-0.91 |
-0.88 |
-0.7 |
-0.5 |
-0.36 |
-0.38 |
-0.79 |
-0.9 |
| Weighted Average Shares Out |
$112.67 M
|
$109.04 M
|
$94.35 M
|
$76.83 M
|
$77.20 M
|
$72.60 M
|
$71.96 M
|
$57.58 M
|
$25.98 M
|
$16.28 M
|
| Weighted Average Shares Out Diluted |
$112.67 M
|
$109.04 M
|
$94.35 M
|
$76.83 M
|
$77.20 M
|
$72.60 M
|
$71.96 M
|
$57.58 M
|
$25.98 M
|
$16.28 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
